LIXTE Biotechnology Holdings (NASDAQ: LIXT) has filed its first-quarter 2026 Form 10-Q, detailing progress in its oncology pipeline and strategic expansion. The company reported advancement of its lead candidate, LB-100, including an expansion of its ovarian cancer trial after favorable safety findings in combination with immunotherapy. LB-100 is a first-in-class clinical PP2A inhibitor that has shown tolerability at doses associated with anti-cancer activity, with potential to enhance chemotherapies and immunotherapies.
The company also highlighted continued growth at its recently acquired subsidiary, Liora Technologies Europe Ltd., which is developing electronically controlled proton therapy systems. Liora’s LiGHT System aims to offer advantages over existing proton therapy technologies for treating tumors. This acquisition aligns with LIXTE’s broader strategy to diversify and strengthen its oncology treatment development capabilities.
LIXTE’s pipeline includes proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. The company’s approach is based on activation lethality, a novel field in cancer biology, supported by a comprehensive patent portfolio. More information is available at www.lixte.com.
The expansion of the ovarian cancer trial marks a key milestone, as LB-100 combined with immunotherapy showed favorable safety, potentially broadening treatment options for patients. The strategic acquisition of Liora Technologies positions LIXTE to integrate advanced proton therapy into its offerings, addressing a growing demand for precise cancer treatments. For updates, visit the company’s newsroom at https://ibn.fm/LIXT.
